Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1) (original) (raw)

Background-To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases. Methods-Data were from REDUCE, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA 2.5-10.0 ng mL −1 and a negative pre-study biopsy. Among men undergoing at least one on-study biopsy with complete data (n = 6415; 78.1%), the association